Pharmacy Services

Duloxetine (Cymbalta®) May Exacerbate Hepatic Injury in Patients with Preexisting Liver Disease

October 8, 2009

Eli Lilly and Company has revised the duloxetine (Cymbalta®) product labeling to include new information about hepatic injury. In postmarketing, duloxetine has been associated with hepatic injury, including hepatitis and cholestatic jaundice, in patients with preexisting chronic liver disease.  To reduce the risk of injury, consider avoiding duloxetine use in patients with preexisting liver disease, any hepatic insufficiency, or substantial alcohol use.  For more information visit the following links:

Updated
October 8, 2009; October 18, 2005; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.